10 April 2025
Incorrect link within Important Safety information for Sodium Valproate
The April monthly update of BNF and BNFC contains an incorrect link within the Important Safety Information section of the Sodium Valproate monograph.
Under the heading MHRA/CHM advice: Valproate (Dyzantil®, Epilim®, Epilim Chrono® or Chronosphere®, Episenta®, and Epival®): review by two specialists is required for initiating valproate but not for male patients already taking valproate (February 2025), the link to the MHRA resources for female patients under 55 years of age is incorrect.
The correct link is: https://assets.publishing.service.gov.uk/media/67adf28c6e6c8d18118acd69/250213_MHRA_Valproate_Infographic_Female_under_55_CC_V7.pdf
A correction is currently underway.
